Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1998-08-25
2003-10-28
Jones, Dwayne C. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06638949
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to methods for the prevention of adhesions, excessive scar formation and other types of abnormal proliferation of tissue using angiogenesis inhibitors.
Scars are the result of wounds that have healed, lesions due to diseases, or surgical operations. Hypertrophic and keloid scars occur when the tissue response is out of proportion to the amount of scar tissue required for normal repair and healing. A keloid scar is a raised, firm, thickened red scar that exceeds the boundary of the injury and may grow for a prolonged period of time. The increase in scar size is due to deposition of all increased amount of collagen into the tissue. African-Americans are genetically prone to developing keloids. Keloid development has been associated with different types of skin injury including surgery, ear piercing, laceration, burns, vaccination or inflammatory process. Common sites are earlobes and the upper trunk and extremities. Surgical removal of keloids alone has been associated with a recurrence rate of 45% to 100%.
The problem of excessive scar formation that manifests itself clinically is a multi-billion dollar problem. For example, intra-abdominal adhesions results in a very significant morbidity and mortality in every surgery practice. Greater than 400,000 hospital admissions in the United States per year are for treatment of pelvic adhesions following surgery. Repeat surgery can greatly aggravate scarring.
There is no effective treatment to prevent adhesions, although numerous different technologies have been tried, including application of barriers which are designed to avoid direct tissue to tissue interactions, and administration of immunosuppressants to decrease inflammatory reactions. Currently there is only one product approved by the FDA for intra-abdominal and one product approved by the FDA for pelvic adhesions. These are principally mechanical barriers to adhesion formation. They are only minimally effective clinically and there remains a huge demand for an alternative. Keloids have been treated with injection of corticosteroid into the scar, by laser therapy, and by administration of pharmacologic agents that interfere with collagen synthesis. Numerous treatments after excision have been used, such as postexcisional injections of corticosteroids or interferon, silicone sheeting, radiotherapy, and pressure splints or garments. See, for example, Berman, et al.,
J. Am. Acad. Dermatol
. 33, 117-123 (1995); Pulton,
Dermatol. Surg
. 21, 947-951 (1995); Cosman, et al.,
Plast. Reconstr. Surg
. 53, 540-543 (1974); Rockwell, et al.,
Plast. Reconstr. Surg
. 827-835 (1989); Griffin, et al.,
Plast. Reconstr. Surg
. 46, 145-150 (1970); Bisley, et al.,
J. Am. Acad. Dermatol
. 35, 113-114 (1996); Klumper, et al.,
J. Acad. Dermatol
. 31, 225-231 (1994); Larrabee, et al.,
Arch. Otolaryngol. Head Neck Surg
. 116, 1159-1162 (1990); Darzi, et al.,
J. Plast. Surg
. 45, 374-379 (1992); and Berman, et al.,
J. Am. Acad. Dermatol
. 37, 755-757 (1997).
It is therefore an object of the present invention to provide a treatment for prevention of excessive scarring and adhesions, without the inhibition of wound healing.
SUMMARY OF THE INVENTION
A method and compositions for inhibiting excessive scar formation and adhesions by administering to a patient in need thereof an effective amount of an angiogenesis inhibitor. In the preferred embodiment, the angiogenesis inhibitor is selective, such as a fumagillol derivative like 0-chloroacetylcarbamoyl-Fumagillol (TNP-470, TAP Pharmaceuticals), thalidomide, or a selective drug having more than one activity, such as minocycline or penicilliamine which also have antibiotic activity. Less selective compounds can also be used, such as the cytokine IL12. Patients to be treated include those having experienced trauma, surgical intervention, burns, and other types of injuries. The inhibitor is administered in an amount effective to decrease excessive scarring, defined as formation of high density tissue including cells and connective tissue, without preventing normal wound closure. The inhibitors can be administered systemically and/or locally or topically, as needed. For prevention of adhesions, the angiogenesis inhibitor would typically be applied at the time of surgery, preferably in a controlled release formulation and/or using barrier technology.
REFERENCES:
patent: 4704383 (1987-11-01), McNamara et al.
patent: 4900815 (1990-02-01), Tanaka et al.
patent: 4925833 (1990-05-01), McNamara et al.
patent: 4935411 (1990-06-01), McNamara et al.
patent: 4975422 (1990-12-01), Kanoh et al.
patent: 5576330 (1996-11-01), Buzzetti et al.
patent: 5605684 (1997-02-01), Piacquadio
patent: 5629340 (1997-05-01), Kuwano et al.
patent: 5670493 (1997-09-01), Cordi et al.
patent: 5674483 (1997-10-01), Tu et al.
patent: 5712291 (1998-01-01), D'Amato
patent: 5792845 (1998-08-01), O'Reilly et al.
patent: 0 325 199 (1989-01-01), None
patent: 325199 (1989-07-01), None
patent: 0 325 199 (1989-07-01), None
patent: WO 95/04142 (1995-02-01), None
patent: WO 95/29242 (1995-11-01), None
patent: WO 97/15666 (1997-05-01), None
Arbiser, “Angiogenesis and the skin: A primer”, J. Amer. Acad. Derm. 34(3):486-497 (1996).
Berman, et al., “Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections,”J. Am. Acad. Dermatol.37: 755-757 (1997).
Berman, et al., “Keloids,”J. Am. Acad. Dermatol.33:117-123 (1995).
Bieley, et al., “Effects of a water-impermeable, non-silicon-based occlusive dressing on keloids,”J. Am. Acad. Dermatol.35: 113-114 (1996).
Brem, H., et al., “Brain tumor angiogenesis.” In: Kornblith, et al.(eds.),Advances in Neuro-Oncology,pp. 89-101. (Future Publishing Co., Mount Kisco, NY (1988).
Brem, et al., “Inhibition of neovascularization by an extract derived from vitreous,”Am. J. Ophthal.84:323-328 (1977).
Brem and Folkman, “Inhibition of tumor angiogenesis mediated by cartilage,”J. Exp. Med.141: 427-439 (1975).
Brem, H., et al., “Inhibition of Tumor Angiogenesis by a Diffusible Factor from Cartilage,” inExtracellular Matrices Influences on Gene Expressionpp. 767-772 (Academic Press, NY 1975).
Cosman, et al., “Bilateral earlobe keloids,”Plast. Reconstr. Surg.53: 540-543 (1974).
Crum, R., et al., “A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment,”Science230: 1375-1378 (1985).
Darzi, et al., “Evaluation of various methods of treating keloids and hypertrophic scars: a 10-year follow-up study,”Br. J. Plast. Surg.45: 374-379 (1992).
Ehrlich, H.P., et al., “Morphological and immunochemical differences between keloid and hypertrophic scar,”Am. J. Pathol.145:105-113 (1994).
Ehrlich, et al., “Hypertrophic scar: an interruption in the remodeling of repair—a laser Doppler blood flow study,”Plast. Reconstr. Surg.90:993-998 (1992).
Eisentein, et al., Growth regulators in connective tissue. Systemic administration of an aortic extract inhibits tumor growth in mice,Am. J. Pathol.9(1): 1-9 (1978).
Folkman, “Angiogenesis and its inhibitors,” inImportant Advances in OncologyDeVita, et al., eds., pp. 42-62, (J. B. Lippincott Co., Philadelphia, 1985).
Folkman, J. “Successful treatment of an angiogenic disease.”N. Engl. J. Med.,320: 1211-1212 (1989).
Folkman, J. “Tumor angiogenesis: therapeutic implications,”N. Engl. J. Med.,285; 1182-1186 (1971).
Folkman, J., et al., “Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone,”Science221: 719-725 (1983).
Folkman, J., et al., “Control of angiogenesis with synthetic heparin substitutes,”Science243: 1490-1493 (1989).
Fulton, “Silicone gel sheeting for the prevention and management of evolving hypertrophic and keloid scars,”Dermatol. Surg.21: 947-951 (1995).
Golub, L. M., et al., “A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity,”J. Dent. Res.,66: 1310-1314 (1987).
Golub, L. M., et al., “Further evidence that tetracyclines inhibit collagenase activity in human crevicular fl
Brem Harold
Ehrlich H. Paul
Folkman Judah
Holland & Knight LLP
Jones Dwayne C.
LandOfFree
Prevention of adhesions and excessive scar formation using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention of adhesions and excessive scar formation using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of adhesions and excessive scar formation using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3174505